Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1997-6-17
|
pubmed:abstractText |
Thirty-two patients with chronic active hepatitis C were initially treated with 9 million units of interferon (IFN)-alpha 2a daily for 4 weeks and then thrice weekly for 20 weeks. The incidence of development and influence on clinical effectiveness of anti-IFN alpha 2a neutralizing antibodies measured by bioassay were investigated. Thirteen (41%) of the 32 patients developed antibodies, 4 (12.5%) of whom exhibited a high titer of 128 NU or greater. There was a significant difference (p < 0.05) between responders and non-responders in the low viral load group (less than 10(5) copies/50 microliters) in the incidence of antibody development, with antibodies present in 2 of the 9 responders (22%) and 5 of the 7 non-responders (71%). There was also a significant difference between the antibody-negative and antibody-positive patients in circulating HCV-RNA, 2-5AS activity and average ALT levels at the latter half of treatment. In addition, 2-5AS activity was significantly lower (p < 0.05) at completion of treatment in the high antibody titer group (128 NU or greater) than in the low antibody titer group. These results indicate that the development of anti-IFN neutralizing antibodies had a definite influence on the clinical course of IFN treatment for chronic hepatitis C.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0446-6586
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
94
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
319-27
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9170879-Adult,
pubmed-meshheading:9170879-Aged,
pubmed-meshheading:9170879-Antibodies,
pubmed-meshheading:9170879-Drug Administration Schedule,
pubmed-meshheading:9170879-Female,
pubmed-meshheading:9170879-Hepacivirus,
pubmed-meshheading:9170879-Hepatitis, Chronic,
pubmed-meshheading:9170879-Hepatitis C,
pubmed-meshheading:9170879-Humans,
pubmed-meshheading:9170879-Interferon-alpha,
pubmed-meshheading:9170879-Male,
pubmed-meshheading:9170879-Middle Aged,
pubmed-meshheading:9170879-RNA, Viral,
pubmed-meshheading:9170879-Recombinant Proteins
|
pubmed:year |
1997
|
pubmed:articleTitle |
[The influence of anti-interferon-alpha 2a antibodies in initial daily four-week interferon-alpha 2a therapy for chronic hepatitis C].
|
pubmed:affiliation |
Department of Gastroenterology, Yodogawa Christian Hospital.
|
pubmed:publicationType |
Journal Article,
English Abstract
|